{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Observation+for+safety&page=2",
    "query": {
      "intervention": "Observation for safety",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Observation+for+safety&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-27T13:37:29.393Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01617629",
      "title": "Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Epithelial Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "MUC1 Dendritic Cell Vaccine (Cvac)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Prima BioMed Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 9,
      "start_date": "2011-12",
      "completion_date": "2014-04",
      "has_results": true,
      "last_update_posted_date": "2017-12-08",
      "last_synced_at": "2026-09-27T13:37:29.393Z",
      "location_count": 5,
      "location_summary": "Greenbrae, California • La Jolla, California • Boca Raton, Florida + 2 more",
      "locations": [
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01617629"
    },
    {
      "nct_id": "NCT03395639",
      "title": "Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cardiac Disease"
      ],
      "interventions": [
        {
          "name": "Edoxaban",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care (SOC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Day",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "1 Day to 17 Years"
      },
      "enrollment_count": 168,
      "start_date": "2018-05-15",
      "completion_date": "2021-12-03",
      "has_results": true,
      "last_update_posted_date": "2022-07-26",
      "last_synced_at": "2026-09-27T13:37:29.393Z",
      "location_count": 14,
      "location_summary": "Birmingham, Alabama • Mesa, Arizona • Los Angeles, California + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03395639"
    },
    {
      "nct_id": "NCT03333941",
      "title": "Continued Access to the Recell® Device for Treatment of Acute Burn Injuries",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Burns"
      ],
      "interventions": [
        {
          "name": "ReCell® Autologous Cell Harvesting Device",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Avita Medical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "5 Years and older"
      },
      "enrollment_count": 76,
      "start_date": "2017-10-26",
      "completion_date": "2019-05-08",
      "has_results": true,
      "last_update_posted_date": "2024-07-30",
      "last_synced_at": "2026-09-27T13:37:29.393Z",
      "location_count": 6,
      "location_summary": "Phoenix, Arizona • Washington D.C., District of Columbia • Tampa, Florida + 3 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03333941"
    },
    {
      "nct_id": "NCT05755620",
      "title": "A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Influenza Virus Quadrivalent Inactivated Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sodium Chloride, 0.9%",
          "type": "OTHER"
        },
        {
          "name": "VRC-FLUNPF099-00-VP (H1ssF_3928)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 50,
      "start_date": "2023-04-05",
      "completion_date": "2025-10-03",
      "has_results": false,
      "last_update_posted_date": "2026-06-18",
      "last_synced_at": "2026-09-27T13:37:29.393Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05755620"
    },
    {
      "nct_id": "NCT03876301",
      "title": "Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Blood Coagulation Disorder",
        "Blood Coagulation Disorders, Inherited",
        "Coagulation Protein Disorders",
        "Hemophilia A",
        "Genetic Diseases, Inborn",
        "Genetic Diseases, X-Linked",
        "Hematologic Diseases",
        "Hemorrhagic Disorders",
        "Factor VIII Deficiency"
      ],
      "interventions": [
        {
          "name": "Standard of Care FVIII Replacement therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Spark Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 25,
      "start_date": "2019-01-21",
      "completion_date": "2023-05-02",
      "has_results": false,
      "last_update_posted_date": "2023-07-10",
      "last_synced_at": "2026-09-27T13:37:29.393Z",
      "location_count": 6,
      "location_summary": "San Francisco, California • Gainesville, Florida • Atlanta, Georgia + 3 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Madison",
          "state": "Mississippi"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03876301"
    },
    {
      "nct_id": "NCT03637465",
      "title": "Increasing Water Access and Appeal in Community Recreation Centers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Health Behavior"
      ],
      "interventions": [
        {
          "name": "Hydrate Philly",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Philadelphia Department of Public Health",
      "sponsor_class": "OTHER_GOV",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "3 Years to 100 Years"
      },
      "enrollment_count": 28,
      "start_date": "2017-05-01",
      "completion_date": "2018-10-30",
      "has_results": false,
      "last_update_posted_date": "2019-04-02",
      "last_synced_at": "2026-09-27T13:37:29.393Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03637465"
    },
    {
      "nct_id": "NCT01460134",
      "title": "A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma",
        "Chronic Lymphocytic Leukemia",
        "Mantle Cell Lymphoma",
        "Marginal Zone B Cell Lymphoma)",
        "Any T-cell Malignancy",
        "Solid Tumors (Metastatic Melanoma, Renal (Clear) Cell Carcinoma",
        "Hormone-refractory Prostate Adenocarcinoma, Ovarian Cancer",
        "Colorectal Adenocarcinoma, Non-small Cell Lung Cancer)",
        "Burkett's Lymphoma",
        "Primary Lymphoma of the Central Nervous System"
      ],
      "interventions": [
        {
          "name": "CDX-1127",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celldex Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2011-10",
      "completion_date": "2017-10-16",
      "has_results": false,
      "last_update_posted_date": "2018-01-31",
      "last_synced_at": "2026-09-27T13:37:29.393Z",
      "location_count": 10,
      "location_summary": "Scottsdale, Arizona • Stanford, California • Rochester, Minnesota + 7 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01460134"
    },
    {
      "nct_id": "NCT03122106",
      "title": "Neoantigen DNA Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Cancer",
        "Pancreas Cancer",
        "Cancer of the Pancreas"
      ],
      "interventions": [
        {
          "name": "Personalized neoantigen DNA vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TDS-IM Electrode Array System",
          "type": "DEVICE"
        },
        {
          "name": "Peripheral blood draws",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE",
        "PROCEDURE"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2018-01-05",
      "completion_date": "2022-08-13",
      "has_results": true,
      "last_update_posted_date": "2023-10-10",
      "last_synced_at": "2026-09-27T13:37:29.393Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • St Louis, Missouri",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03122106"
    },
    {
      "nct_id": "NCT05747209",
      "title": "EXErcise Regimen Designed to Improve Functional Mobility, Body Composition, and Strength After Treatment for Breast CA",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer Female"
      ],
      "interventions": [
        {
          "name": "Observation of Exercise Program Adherence",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Colin Champ, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "89 Years",
        "sex": "FEMALE",
        "summary": "20 Years to 89 Years · Female only"
      },
      "enrollment_count": 43,
      "start_date": "2022-10-01",
      "completion_date": "2024-09-19",
      "has_results": true,
      "last_update_posted_date": "2025-06-24",
      "last_synced_at": "2026-09-27T13:37:29.393Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05747209"
    },
    {
      "nct_id": "NCT05718570",
      "title": "A Study to Follow Patients With Adult Growth Hormone Deficiency (AGHD) Treated With Sogroya® for Long Term Safety Information",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Adult Growth Hormone Deficiency"
      ],
      "interventions": [
        {
          "name": "Somapacitan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 400,
      "start_date": "2023-02-03",
      "completion_date": "2032-12-15",
      "has_results": false,
      "last_update_posted_date": "2026-06-12",
      "last_synced_at": "2026-09-27T13:37:29.393Z",
      "location_count": 29,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 20 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Westminster",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05718570"
    }
  ]
}